Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.47 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442691 | 0.87 | DPP4 (0.53) | DPP4DPP8DPP9DPP7OPRM1 | |
| SCHEMBL13413212 | 0.83 | FKBP1A (0.57) | DPP4DPP8DPP9DPP7ACE2 | |
| SCHEMBL13034341 | 0.81 | XIAP (0.45) | ABHD6DAGLAACE2 | |
| SCHEMBL19617254 | 0.80 | ABHD6 (0.56) | DPP4ABHD6DAGLA | |
| SCHEMBL15811762 | 0.80 | ABHD6 (0.56) | DPP4ABHD6DAGLA | |
| SCHEMBL6360197 | 0.80 | ABHD6 (0.56) | DPP4ABHD6DAGLA | |
| SCHEMBL4665023 | 0.80 | DPP4 (0.48) | DPP4DPP8DPP9DPP7OPRM1 | |
| SCHEMBL6789297 | 0.79 | FKBP1A (0.53) | — | |
| SCHEMBL6789293 | 0.79 | FKBP1A (0.53) | — | |
| SCHEMBL13034339 | 0.79 | STAT6 (0.46) | ABHD6DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | SCHEINBERG DAVID | 2005-12-08 | — | — | US | disclosed |
| EP-1372692-A4 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INST CANCER (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6887887-B2 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-29 | — | — | US | disclosed |
| EP-1372692-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | Sloan Kettering Institute For Cancer Research (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6660741-B2 | Coupling an O-protected methoxypyrrolidine or derivatives with N-protected amino acid 2,5-dioxo-pyrrolidinyl ester to form intermediate, deportecting with trifluoroacetic acid to form pyrrolidine-1-carbonyl-2-methylamine or derivatives | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | disclosed |
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2002-12-26 | — | — | US | disclosed |
| WO-2002074050-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198156-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, ACTR3 | DPP4 4678/4885DPP8 4804/4885DPP9 4880/4885 |
| US-20040019083-A1 | Asymmetric synthesis of (S,S,R)-(-)-actinonin and its analogs and uses therefor | HASPIN, CYTH2, CYTH3 | DPP4 4641/4885DPP8 4783/4885DPP9 4880/4885 |
| US-20050272667-A1 | Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor | CYTH3, ACTR3, HASPIN | DPP4 4609/4885DPP8 4753/4885DPP9 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.